Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson’s Disease
Antioxidants · 06.04.2023 · 12 (4) · 894
DOI: 10.3390/antiox12040894 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 06.04.2023. Verfasst von Ikuko Miyazaki und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, the Okayama Medical Foundation, the grant from All Japan Coffee Association.
Abstract (Originalsprache)
Parkinson’s disease (PD) is characterized by motor symptoms based on a loss of nigrostriatal dopaminergic neurons and by non-motor symptoms which precede motor symptoms. Neurodegeneration accompanied by an accumulation of α-synuclein is thought to propagate from the enteric nervous system to the central nervous system. The pathogenesis in sporadic PD remains unknown. However, many reports indicate various etiological factors, such as oxidative stress, inflammation, α-synuclein toxicity and mitochondrial impairment, drive neurodegeneration. Exposure to heavy metals contributes to these etiopathogenesis and increases the risk of developing PD. Metallothioneins (MTs) are cysteine-rich metal-binding proteins; MTs chelate metals and inhibit metal-induced oxidative stress, inflammation and mitochondrial dysfunction. In addition, MTs possess antioxidative properties by scavenging free radicals and exert anti-inflammatory effects by suppression of microglial activation. Furthermore, MTs recently received attention as a potential target for attenuating metal-induced α-synuclein aggregation. In this article, we summarize MTs expression in the central and enteric nervous system, and review protective functions of MTs against etiopathogenesis in PD. We also discuss neuroprotective strategies for the prevention of central dopaminergic and enteric neurodegeneration by targeting MTs. This review highlights multifunctional MTs as a target for the development of disease-modifying drugs for PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Neurobiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
ORCID-Profile: Ikuko Miyazaki, Masato Asanuma
Förderung
- Japan Society for the Promotion of Science
- the Okayama Medical Foundation
- the grant from All Japan Coffee Association
- the grant from Japanese Society of Eucommia
- JSPS KAKENHI Grant for Scientific Research
- Okayama Medical Foundation
- All Japan Coffee Association
- Japanese Society of Eucommia
Zitieren
APA
Miyazaki, I., & Asanuma, M. (2023). Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson’s Disease. Antioxidants, 12(4), 894. https://doi.org/10.3390/antiox12040894
Vancouver
Miyazaki I, Asanuma M. Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson’s Disease. Antioxidants. 2023;12(4):894. doi:10.3390/antiox12040894
BibTeX
@article{Miyazaki2023,
author = {Miyazaki, Ikuko and Asanuma, Masato},
title = {Multifunctional Metallothioneins as a Target for Neuroprotection in Parkinson’s Disease},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {4},
pages = {894},
doi = {10.3390/antiox12040894}
}
EUVIMED